Genitourinary Cancers | Specialty

United in Tulsa: Urologic Specialists of Oklahoma Is a Model of Collaboration

October 4th 2013

USO co-founders John Forrest, MD, and Robert Bruce, MD, have known each other since the fourth grade. They both attended medical school at the University of Oklahoma and, after some time away from home, ultimately joined two different, well-established practices in north and south Tulsa.

Dovitinib Fails as Third-Line Option in Kidney Cancer

October 3rd 2013

Dovitinib failed to meet the primary endpoint of improving progression-free survival versus sorafenib (Nexavar) in patients with heavily pretreated progressive renal cell carcinoma

Dr. Schmidinger on Targeted Agent Side Effects in RCC

October 2nd 2013

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted agents in renal cell cancer, including hypertension, diarrhea, and hand-foot syndrome.

Dr. Grünwald on Dovitinib Versus Sorafenib in mRCC

September 30th 2013

Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.

Dr. George on Critical Clinical Trials in Kidney Cancer

September 30th 2013

Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.

Lower Bladder Cancer Risk Seen in Marijuana Users

September 26th 2013

Marijuana users had a small but statistically lower risk of bladder cancer compared with people who smoked tobacco or did not smoke.

First-Line Standard for Metastatic RCC Upheld

September 12th 2013

The standard of care for metastatic renal cell carcinoma (RCC) prevailed in a randomized comparison of everolimus (Afinitor) and sunitinib (Sutent) as first-line therapy

Dr. Sosman on Immunotherapy in Melanoma and Renal Cancer

August 28th 2013

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Pazopanib Less Toxic Than Sunitinib in RCC

August 22nd 2013

Patients with advanced renal cell carcinoma could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

Taking Care of Business: Regional Urology Offers Consistent Care Despite Tumultuous Times

August 22nd 2013

Change may not always be pleasant, but it is inevitable, and nowhere has that been more evident recently than in US healthcare; however, for the physicians at Regional Urology in Shreveport, Louisiana, these changes are really just business as usual.

The Urologist in the World of Personalized Medicine

August 21st 2013

We should move away from directing therapy based on the primary site of malignancy and focus our efforts on inherent pathways common to the tumors, irrespective of the organ.

Nivolumab Benefits Durable in Three Tumor Types

August 19th 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Data Support Safety and Benefit of Chemotherapy Before Radical Cystectomy

August 14th 2013

Preoperative chemotherapy was not a predictor of postoperative complications, nor did it increase the length of hospital stays or surgical complications among patients undergoing radical cystectomy for muscle-invasive bladder cancer.

In Some Renal Cell Tumors, Volume More Prognostic Than Size

August 7th 2013

Current T staging for renal cell carcinoma does not capture the full picture of tumor volume, which data have shown to be more predictive of survival and recurrence in certain types of cancer.

Prostate Cancer Gene Test Could Boost Active Surveillance

July 25th 2013

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.

Conclusion: Key Take-Away Points and Cardiac Safety

July 1st 2013

Unmet Needs in Renal Cell Carcinoma

July 1st 2013

Immune Checkpoint Inhibition in Renal Cell Carcinoma

July 1st 2013

Novel Agents in Development for Renal Cell Carcinoma

July 1st 2013

INTORSECT Trial: Second-Line Temsirolimus Versus Sorafenib

July 1st 2013